Patrick Aebischer
+41 21 693 21 01
EPFL › SV › SV-SSV › SSV-ENS
Site web: https://sv.epfl.ch/education
Patrick Aebischer a achevé une formation en Médecine (1980) et en Neurosciences (1983) aux Universités de Genève et de Fribourg en Suisse.
De 1984 à 1992, Patrick Aebischer a travaillé à Brown University (USA) au sein du Département des Neurosciences et au Département des Biomatériaux et des Organes Artificiels en tant que Professeur assistant, puis Professeur associé.
En 1992, Patrick Aebischer a été nommé Professeur de la Division Autonome de Recherche Chirurgicale et du Centre de Thérapie Génique (DARC) au Centre Hospitalier Universitaire Vaudois (CHUV) à Lausanne.
En 1999, Le Conseil Fédéral a nommé Patrick Aebischer en tant que Président de l'Ecole Polytechnique Fédérale de Lausanne (EPFL). Il a pris ses fonctions à la Présidence de l'EPFL en mars 2000, position qu'il a occupée jusqu'au 31 décembre 2016.
Patrick Aebischer est membre de maintes sociétés professionnelles, tant en Europe qu'aux Etats-Unis.
Patrick Aebischer a fondé trois start-up de biotechnologies. Il siège au conseil d'administration de Lonza, de Logitech et de Nestlé. Il préside également l'advisory board du Novartis Venture Fund. Patrick Aebischer est membre du conseil de fondation du Festival de Jazz de Montreux, du Festival de Verbier et de la Fondation Jacobs.
Les recherches qu'il poursuit actuellement dans son laboratoire se concentrent sur le développement d'approches de thérapie cellulaire et de transfert génique pour le traitement des maladies neurodégénératives.
Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults
Cell Reports Medicine. 2022. DOI : 10.1016/j.xcrm.2022.100633.Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults A Randomized Clinical Trial
Jama Network Open. 2022. DOI : 10.1001/jamanetworkopen.2021.44279.Astrocyte-targeting RNA interference against mutated superoxide dismutase 1 induces motoneuron plasticity and protects fast-fatigable motor units in a mouse model of amyotrophic lateral sclerosis
Glia. 2022. DOI : 10.1002/glia.24140.Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population
European Journal Of Clinical Nutrition. 2021. DOI : 10.1038/s41430-021-00950-1.Evolution of the neurochemical profiles in the G93A-SOD1 mouse model of amyotrophic lateral sclerosis
Journal of Cerebral Blood Flow & Metabolism. 2019. DOI : 10.1177/0271678X18756499.The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans
Nature Metabolism. 2019. DOI : 10.1038/s42255-019-0073-4.A viral vector based in vivo model of tauopathy to explore therapeutic strategies against tau pathology
Lausanne, EPFL, 2019. DOI : 10.5075/epfl-thesis-9532.Application of anti-amyloid beta immunization using encapsulated cell technology in mouse models of Alzheimer's disease
Lausanne, EPFL, 2019. DOI : 10.5075/epfl-thesis-9751.Cas9/gRNA selective targeting of the Beethoven tmc-1 mutant allele for treating progressive hearing loss by AAV-based delivery
2018. Conference on Changing the Face of Modern Medicine - Stem Cell and Gene Therapy, Lausanne, SWITZERLAND, Oct 16-19, 2018. p. A107 - A108.Cas9/gRNAs Selective Targeting of the Beethoven Tmc-1 Mutant Allele for Treating Progressive Hearing Loss by AAV-Based Delivery
2018. 21st Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Chicago, IL, May 16-19, 2018. p. 138 - 139.AAV based gene therapy for rare diseases : targeting astrocytes for functional recovery in Amyotrophic Lateral Sclerosis
Lausanne, EPFL, 2017. DOI : 10.5075/epfl-thesis-7888.The effect of the functional interaction between PGC-1α and Parkin on mitochondrial quality control in Parkinson's disease
Lausanne, EPFL, 2016. DOI : 10.5075/epfl-thesis-6868.Use of a Bicistronic Vector to Silence SOD1 in Motoneurons and Astrocytes for the Treatment of Familial Amyotrophic Lateral Sclerosis
2016. 19th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Washington, DC, MAY 04-07, 2016. p. S240 - S240.Modulation of AMPK's activity via genetic tools and food-derived compounds as a novel approach to Parkinson's disease treatment
Lausanne, EPFL, 2016. DOI : 10.5075/epfl-thesis-6978.In Vivo Evidence for a Lactate Gradient from Astrocytes to Neurons
Cell Metabolism. 2016. DOI : 10.1016/j.cmet.2015.10.010.Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents
Nat Med. 2016. DOI : 10.1038/nm.4132.A subcutaneous cellular implant for passive immunization against amyloid-beta reduces brain amyloid and tau pathologies
Brain. 2016. DOI : 10.1093/brain/aww036.Tmc gene therapy restores auditory function in deaf mice
Science Translational Medicine. 2015. DOI : 10.1126/scitranslmed.aab1996.Alpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease
Biomolecules. 2015. DOI : 10.3390/biom5042675.Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology
Experimental neurology. 2015. DOI : 10.1016/j.expneurol.2014.11.013.Channel-Mediated Lactate Release by K+-Stimulated Astrocytes
The Journal of neuroscience. 2015. DOI : 10.1523/Jneurosci.5036-14.2015.SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice
Annals Of Clinical And Translational Neurology. 2015. DOI : 10.1002/acn3.162.Neuronal Matrix Metalloproteinase-9 Is a Determinant of Selective Neurodegeneration
Neuron. 2014. DOI : 10.1016/j.neuron.2013.12.009.Genetic engineering of cell lines using lentiviral vectors to achieve antibody secretion following encapsulated implantation
Biomaterials. 2014. DOI : 10.1016/j.biomaterials.2013.10.026.Intracerebroventricular Injection of Adeno-Associated Virus 6 and 9 Vectors for Cell Type-Specific Transgene Expression in the Spinal Cord
Human Gene Therapy. 2014. DOI : 10.1089/hum.2013.021.A high-capacity cell macroencapsulation system supporting the long-term survival of genetically engineered allogeneic cells
Biomaterials. 2014. DOI : 10.1016/j.biomaterials.2013.09.071.A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity
Human Molecular Genetics. 2014. DOI : 10.1093/hmg/ddu202.AAV-mediated gene therapy against motoneuron diseases
Lausanne, EPFL, 2013. DOI : 10.5075/epfl-thesis-5821.A novel encapsulation device for peripheral implantation of antibody-secreting cells : passive immunization against amyloid β
Lausanne, EPFL, 2013. DOI : 10.5075/epfl-thesis-5796.Direct and Retrograde Transduction of Nigral Neurons with AAV6, 8, and 9 and Intraneuronal Persistence of Viral Particles
Human Gene Therapy. 2013. DOI : 10.1089/hum.2012.174.Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo
Proceedings Of The National Academy Of Sciences Of The United States Of America (PNAS). 2013. DOI : 10.1073/pnas.1309991110.Astrocyte–neuron co-culture on microchips based on the model of SOD mutation to mimic ALS
Integrative Biology. 2013. DOI : 10.1039/c3ib40022k.Synergistic Effects of GDNF and VEGF on Lifespan and Disease Progression in a Familial ALS Rat Model
Molecular Therapy. 2013. DOI : 10.1038/mt.2013.108.An in vivo ultrahigh field 14.1 T (1) H-MRS study on 6-OHDA and α-synuclein-based rat models of Parkinson's disease: GABA as an early disease marker
NMR in biomedicine. 2013. DOI : 10.1002/nbm.2817.Focal expression of adeno-associated viral-mutant tau induces widespread impairment in an APP mouse model
Neurobiology Of Aging. 2013. DOI : 10.1016/j.neurobiolaging.2012.11.011.Use of viral vectors to create animal models for Parkinson's disease
Neurobiology Of Disease. 2012. DOI : 10.1016/j.nbd.2011.12.038.Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function
Human Molecular Genetics. 2012. DOI : 10.1093/hmg/ddr618.Proton and phosphorus magnetic resonance spectroscopy of a mouse model of Alzheimer's disease
Journal of Alzheimer's disease : JAD. 2012. DOI : 10.3233/JAD-2012-112072.Parkinson's Disease: Gene Therapies
Cold Spring Harbor Perspectives In Medicine. 2012. DOI : 10.1101/cshperspect.a009431.α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer
Journal of Biological Chemistry. 2012. DOI : 10.1074/jbc.M111.318949.Imaging brain amyloid deposition using grating-based differential phase contrast tomography
Neuroimage. 2012. DOI : 10.1016/j.neuroimage.2012.03.029.Role of the FoxO3a Transcription Factor in alpha-synuclein Induced Neurodegeneration
Lausanne, EPFL, 2012. DOI : 10.5075/epfl-thesis-5245.Mimicking Phosphorylation at Serine 87 Inhibits the Aggregation of Human α-Synuclein and Protects against Its Toxicity in a Rat Model of Parkinson's Disease
The Journal of neuroscience : the official journal of the Society for Neuroscience. 2012. DOI : 10.1523/JNEUROSCI.3784-11.2012.How to build science capacity
Nature. 2012. DOI : 10.1038/490331a.Philanthropy: The price of charity
Nature. 2012. DOI : 10.1038/481260a.Proton and phosphorus MRS of a 5xFAD mouse model of Alzheimer's disease
2011. ISMRM 19th Annual Meeting & Exhibition, Montreal, Canada, May 7-13, 2011.Investigation of the role of PICALM on amyloid metabolism in a transgenic mouse model of Alzheimer’s disease
2011Early metabolic changes in the amyotrophic lateral sclerosis SOD1 mouse brain are revealed using 1H MRS rather than CASL and 18FDG PET
2011. 19th Scientific Meeting of the International Society for Magnetic Resonance in Medicine, 2011, Montréal, Québec, Canada.A Rat Model of Progressive Nigral Neurodegeneration Induced by the Parkinson's Disease-Associated G2019S Mutation in LRRK2
Journal of Neuroscience. 2011. DOI : 10.1523/JNEUROSCI.5092-10.2011.Chronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination tool
Plos One. 2011. DOI : 10.1371/journal.pone.0018268.Alpha-Synuclein Effects at the ER-to-Golgi Level and Potential Biomarkers in Rat Models of the Early Phase of Parkinson's Disease
Lausanne, EPFL, 2011. DOI : 10.5075/epfl-thesis-5176.Rab1A Over-Expression Prevents Golgi Apparatus Fragmentation and Partially Corrects Motor Deficits in an Alpha-Synuclein Based Rat Model of Parkinson’s Disease
Journal of Parkinson's Disease. 2011. DOI : 10.3233/JPD-2011-11058.Use of igf-1 and nt-3 in the treatment of x-linked adrenoleukodystrophy
WO2010089706 . 2010.Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6
Gene Therapy. 2010. DOI : 10.1038/gt.2009.119.Motor Deficits upon Alpha-Synuclein Expression in the Nigrostriatal System Are Due to a Loss of Dopaminergic Vesicles and Reduced Dopamine Release at an early Stage of Neurodegeneration
Lausanne, EPFL, 2010. DOI : 10.5075/epfl-thesis-4765.Alpha-Synuclein Animal Models
2010. 2nd World Parkinson Congress, Glasgow, UK, September 28 - October 1, 2010. p. S606 - S606.Neuroprotection by Gene Therapy Targeting Mutant SOD1 in Individual Pools of Motor Neurons Does not Translate Into Therapeutic Benefit in fALS Mice
Molecular therapy : the journal of the American Society of Gene Therapy. 2010. DOI : 10.1038/mt.2010.260.Neurodegenerative Disorders: Gene Therapy on Clinical Trial
Frontiers in Neuroscience. 2010.Effective Delivery of the Neuroprotectant to the Brain
2010. 2nd World Parkinson Congress, Glasgow, UK, September 28 - October 1, 2010. p. S602 - S602.Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions
The Journal of neuroscience : the official journal of the Society for Neuroscience. 2010. DOI : 10.1523/JNEUROSCI.5922-09.2010.Adeno-Associated Virus-Mediated Gene Delivery for the Treatment of Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders
Lausanne, EPFL, 2010. DOI : 10.5075/epfl-thesis-4669.Collapsin response médiator protein 4a(CRMP 4a) is upregulated in motoneurons of mutant SOD1 mice and can trigger motoneuron death
The Journal of neuroscience. 2010. DOI : 10.1523/JNEUROSCI.5411-09.2010.AAV-mediated expression of wild-type and ALS-linked mutant VAPB selectively triggers death of motoneurons through a Ca2+-dependent ER-associated pathway
Journal of Neurochemistry (JNC). 2010. DOI : 10.1111/j.1471-4159.2010.06806.x.Modeling Parkinson's Disease in Adult Rats Using Viral Vectors as Gene Delivery Tools
Lausanne, EPFL, 2010. DOI : 10.5075/epfl-thesis-4758.Grafts of Dopamine Neurons Can Send Neurites to the Striatum Under GDNF Inducement in a Nonhuman Primate
2009. 16th Annual Meeting of the American-Society-for-Neural-Therapy-and-Repair, Clearwater Beach, FL, Apr 30-May 02, 2009. p. 234 - 235.Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons
Molecular Therapy. 2009. DOI : 10.1038/mt.2009.142.An in vivo culture system for human embryos using an encapsulation technology: a pilot study
Human Reproduction. 2009. DOI : 10.1093/humrep/dep005.Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease
Neurobiology of disease. 2009. DOI : 10.1016/j.nbd.2009.03.013.Implication of the JNK pathway in a rat model of Huntington's disease
Experimental Neurology. 2009. DOI : 10.1016/j.expneurol.2008.10.008.Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF
Neurobiology of Disease. 2009. DOI : 10.1016/j.nbd.2009.07.022.Embryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in non-human primate after overexpression of GDNF
Journal of Comparative Neurology. 2009. DOI : 10.1002/cne.22028.Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions
Neurobiology of Disease. 2009. DOI : 10.1016/j.nbd.2009.05.023.Immunoisolated cell implants for intracerebral delivery of anti-Aß single chain Fv antibodies in the APP23 Alzheimer's mouse model
Lausanne, EPFL, 2009. DOI : 10.5075/epfl-thesis-4464.Regulation of Episomal Gene Expression by KRAB/KAP1-Mediated Histone Modifications
Journal of Virology. 2009. DOI : 10.1128/JVI.00001-09.Lentiviral and Adeno-Associated Vector-Based Therapy for Motor Neuron Disease Through RNAi
Therapeutic Applications of RNAi; 2009. p. 87 - 108.Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease
Human Molecular Genetics. 2009. DOI : 10.1093/hmg/ddn417.Insulin-like growth factor-1 and neurotrophin-3 gene therapy prevents motor decline in an X-linked adrenoleukodystrophy mouse model
Annals of Neurology. 2009. DOI : 10.1002/ana.21677.Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery
Molecular Pain. 2009. DOI : 10.1186/1744-8069-5-52.Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease
The Journal of clinical investigation. 2008. DOI : 10.1172/JCI35781.Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice
Molecular Therapy. 2008. DOI : 10.1038/mt.2008.73.Delta-like 1 participates in the specification of ventral midbrain progenitor derived dopaminergic neurons
Journal of Neurochemistry (JNC). 2008. DOI : 10.1111/j.1471-4159.2007.05037.x.Feasibility of gene therapy for the treatment of neuropathic pain: downregulation of GTP cyclohydrolase 1 expression via RNA interference
2008. p. 3S - 3S.Neuropathic pain: Gene therapy as a tool to transduce nociceptors
2008. p. 12S - 12S.Development Of A Cell Encapsulation Approach For Human Anti-Tumor Immunotherapy
2008. XXXV Congress of the European Society for Artificial Organs: 'Towards Future Biomedical Technologies. p. 601 - 601.Impact of phosphorylation of alpha-synuclein in Parkinson's disease
Lausanne, EPFL, 2008. DOI : 10.5075/epfl-thesis-4069.Intramuscular delivery of GDNF with human mesenchymal stem cells protects dying motor neurons and prolongs survival in a rat model of familial ALS
2008. 15th Annual Meeting of the American-Society-for-Neural-Therapy-and-Repair, Clearwater Beach, FL, May 01-03, 2008. p. 482 - 483.Conditional gene expression and knockdown using lentivirus vectors encoding shRNA
Methods Mol Biol. 2008. DOI : 10.1007/978-1-60327-248-3_18.Viral vectors: a potent approach to generate genetic models of Parkinson's disease
Parkinson's disease: Molecular and therapeutics insights from model systems; New York: Academic Press, 2008. p. 269 - 284.Viral vectors, animal models and new therapies for Parkinson's disease
Parkinsonism Realted Disorders. 2008. DOI : 10.1016/j.parkreldis.2008.04.024.GDNF-secreting human neural progenitor cells increase tyrosine hydroxylase and VMAT2 expression in MPTP-treated cynomolgus monkeys
Cell Transplant. 2008. DOI : 10.3727/096368908784423300.Direct Muscle Delivery of GDNF With Human Mesenchymal Stem Cells Improves Motor Neuron Survival and Function in a Rat Model of Familial ALS
Molecular Therapy. 2008. DOI : 10.1038/mt.2008.197.Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry
The Journal of neuroscience. 2008. DOI : 10.1523/JNEUROSCI.3044-08.2008.Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation
Human Molecular Genetics. 2007. DOI : 10.1093/hmg/ddm008.From gene to gene therapy and pharmacotherapy, via transgenic animals
2007. 11th Congress of the European-Federation-of-Neurological-Societies, Brussels, BELGIUM, Aug 25-28, 2007. p. 2 - 2.Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates
Molecular Therapy. 2007. DOI : 10.1038/sj.mt.6300185.Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease
Molecular Therapy. 2007. DOI : 10.1038/mt.sj.6300141.Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy
Journal of Neuroscience Methods. 2007. DOI : 10.1016/j.jneumeth.2007.02.022.DJ-1 as a neuroprotective protein in models of Parkinson's disease
Lausanne, EPFL, 2007. DOI : 10.5075/epfl-thesis-3926.Metabolic correction in oligodendrocytes derived from metachromatic leukodystrophy mouse model by using encapsulated recombinant myoblasts
J Neurol Sci. 2007. DOI : 10.1016/j.jns.2007.01.010.The KRAB repressor domain can trigger de novo promoter methylation during mouse early embryogenesis
Journal of Biological Chemistry. 2007. DOI : 10.1074/jbc.M705898200.Playing Defense Against Lou Gehrig's Disease
Scientific American. 2007. DOI : 10.1038/scientificamerican1107-86.GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS
PLoS ONE. 2007. DOI : 10.1371/journal.pone.0000689.Inducing tolerance to a soluble foreign antigen by encapsulated cell transplants
Molecular Therapy. 2006. DOI : 10.1016/j.ymthe.2005.08.010.Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates
Gene Therapy. 2006. DOI : 10.1038/sj.gt.3302679.A versatile tool for conditional gene expression and knockdown
Nature Methods. 2006. DOI : 10.1038/nmeth846.Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease
Neurobiol Dis. 2006. DOI : 10.1016/j.nbd.2005.10.006.Chronic activation in presymptomatic amyotrophic lateral sclerosis (ALS) mice of a feedback loop involving Fas, Daxx, and FasL
Proceedings Of The National Academy Of Sciences Of The United States Of America (PNAS). 2006. DOI : 10.1073/pnas.0508774103.Lentivirus-mediated expression of glutathione peroxidase: neuroprotection in murine models of Parkinson's disease
Neurobiol Dis. 2006. DOI : 10.1016/j.nbd.2005.06.003.The potential of gene therapy for motor neuron diseases
Amyotrophic Lateral Sclerosis; New York, NY: Taylor&Francis, 2006. p. 505 - 524.Viral vectors as a tool to model and treat Parkinson's disease
Wien Klin Wochenschr. 2006. DOI : 10.1007/s00508-006-0736-5.Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421
The Journal of neuroscience. 2006. DOI : 10.1523/JNEUROSCI.3706-05.2006.Viral-based modelling and correction of neurodegenerative diseases by RNA interference
Gene therapy. 2006. DOI : 10.1038/sj.gt.3302690.CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant huntingtin neurotoxicity
The Journal of neuroscience. 2006. DOI : 10.1523/JNEUROSCI.5409-05.2006.Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment
Neurobiol Dis. 2005. DOI : 10.1016/j.nbd.2005.05.017.Transgenic SOD1 mice as a model for developing amyotrophic lateral sclerosis therapies
Lausanne, EPFL, 2005. DOI : 10.5075/epfl-thesis-3331.Use of lentiviral vectors for modelling and treating Parkinson's disease
Lausanne, EPFL, 2005. DOI : 10.5075/epfl-thesis-3167.GDNF delivery using human neural progenitor cells in a rat model of ALS
Human Gene Therapy. 2005. DOI : 10.1089/hum.2005.16.509.Akt is altered in an animal model of Huntington's disease and in patients
European Journal of Neuroscience. 2005. DOI : 10.1111/j.1460-9568.2005.03985.x.Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS
Nature Medicine. 2005. DOI : 10.1038/nm1207.Increased fiber outgrowth from xeno-transplanted human embryonic dopaminergic neurons with co-implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor
Brain Res Bull. 2005. DOI : 10.1016/j.brainresbull.2005.04.009.Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production
Journal of Neurochemistry (JNC). 2005. DOI : 10.1111/j.1471-4159.2005.03139.x.Dopaminergic fiber protection and regeneration by Wlds protein and GDNF in rodent models of Parkinson disease
Lausanne, EPFL, 2005. DOI : 10.5075/epfl-thesis-3265.Huntington's disease modeling and treatment : from primary neuronal cultures to rodents
Lausanne, EPFL, 2005. DOI : 10.5075/epfl-thesis-3137.ALS, IGF-1 and gene therapy: 'it's never too late to mend'
Gene Therapy. 2004. DOI : 10.1038/sj.gt.3302204.Local GDNF expression mediated by lentiviral vector protects facial nerve motoneurons but not spinal motoneurons in SOD1(G93A) transgenic mice
Neurobiol Dis. 2004. DOI : 10.1016/j.nbd.2004.01.017.Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease
Neurobiol Dis. 2004. DOI : 10.1016/j.nbd.2004.06.008.Lentiviral-mediated gene transfer to model triplet repeat disorders
Methods Mol Biol. 2004. DOI : 10.1385/1-59259-804-8:199.Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study
Human Gene Therapy. 2004. DOI : 10.1089/hum.2004.15.968.Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice
Exp Neurol. 2004. DOI : 10.1016/j.expneurol.2003.09.002.Salivary glands and gene therapy: the mouth waters
Gene Therapy. 2004. DOI : 10.1038/sj.gt.3302321.In vivo calcium deposition on polyvinyl alcohol matrix used in hollow fiber cell macroencapsulation devices
Biomaterials. 2004. DOI : 10.1016/j.biomaterials.2003.10.030.Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease
Proceedings Of The National Academy Of Sciences Of The United States Of America (PNAS). 2004. DOI : 10.1073/pnas.0405313101.Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions
Human Gene Therapy. 2004. DOI : 10.1089/1043034041361172.Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease
Current Biology. 2004. DOI : 10.1016/S0960-9822(04)00050-8.Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons
Neurobiol Dis. 2004. DOI : 10.1016/j.nbd.2004.03.012.Cellular implants: pioneers in xenotransplantation?
Xenotransplantation. 2003. DOI : 10.1034/j.1399-3089.2003.02086.x.Enhancement of peripheral nerve regeneration by interactive biomaterials
Lausanne, EPFL, 2003. DOI : 10.5075/epfl-thesis-2423.Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum
Human Molecular Genetics. 2003. DOI : 10.1093/hmg/ddg305.Cell therapy using encapsulated cells producing endostatin
Local Therapies for Glioma; New York, NY: Springer, 2003. p. 137 - 141.Presence of Gal-alpha1,3Gal epitope on xenogeneic lines: implications for cellular gene therapy based on the encapsulation technology
Xenotransplantation. 2003. DOI : 10.1034/j.1399-3089.2003.00110.x.Activity analysis of housekeeping promoters using self-inactivating lentiviral vector delivery into the mouse retina
Gene Therapy. 2003. DOI : 10.1038/sj.gt.3301948.Optimization of human erythropoietin secretion from MLV-infected human primary fibroblasts used for encapsulated cell therapy
J Gene Med. 2003. DOI : 10.1002/jgm.338.Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery
Molecular Therapy. 2003. DOI : 10.1016/S1525-0016(03)00055-8.Comparative study of GDNF delivery systems for the CNS: polymer rods, encapsulated cells, and lentiviral vectors
J Control Release. 2003. DOI : 10.1016/S0168-3659(02)00353-X.Lentiviral-mediated RNA interference
Human Gene Therapy. 2002. DOI : 10.1089/104303402320987888.GDNF and NGF released by synthetic guidance channels support sciatic nerve regeneration across a long gap
European Journal of Neuroscience. 2002. DOI : 10.1046/j.1460-9568.2002.01892.x.Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length
The Journal of neuroscience. 2002. DOI : 10.1523/JNEUROSCI.22-09-03473.2002.Allogeneic beta-islet cells correct diabetes and resist immune rejection
Proceedings Of The National Academy Of Sciences Of The United States Of America (PNAS). 2002. DOI : 10.1073/pnas.122241299.Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts
Molecular Therapy. 2002. DOI : 10.1006/mthe.2002.0646.Encapsulation as a strategy for cell xenotransplantation
Future strategies for tissue and organ replacement; London: Imperial College Press, 2002. p. 291 - 322.Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia
Kidney Int. 2002. DOI : 10.1111/j.1523-1755.2002.kid574.x.Lentiviruses as vectors for CNS diseases
Current topics in microbiology and immunology. 2002. DOI : 10.1007/978-3-642-56114-6_10.alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease
Proceedings Of The National Academy Of Sciences Of The United States Of America (PNAS). 2002. DOI : 10.1073/pnas.152339799.Simultaneous GDNF and BDNF application leads to increased motoneuron survival and improved functional outcome in an experimental model for obstetric brachial plexus lesions
Plast Reconstr Surg. 2002. DOI : 10.1097/01.PRS.0000020990.82332.43.Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease
Human Gene Therapy. 2002. DOI : 10.1089/10430340260355383.Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons
Journal of Neuroscience Res. 2002. DOI : 10.1002/jnr.10396.Glial cell line-derived neurotrophic factor released by synthetic guidance channels promotes facial nerve regeneration in the rat
Journal of Neuroscience Res. 2002. DOI : 10.1002/jnr.10434.Seizure suppression by adenosine-releasing cells is independent of seizure frequency
Epilepsia. 2002. DOI : 10.1046/j.1528-1157.2002.33001.x.Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration
The Journal of neuroscience. 2002. DOI : 10.1523/JNEUROSCI.22-12-04942.2002.Isolation of multipotent neural precursors residing in the cortex of the adult human brain
Exp Neurol. 2001. DOI : 10.1006/exnr.2001.7691.Inducing host acceptance to encapsulated xenogeneic myoblasts
Transplantation. 2001. DOI : 10.1097/00007890-200102150-00002.Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy
Proceedings Of The National Academy Of Sciences Of The United States Of America (PNAS). 2001. DOI : 10.1073/pnas.131102898.A self-immunomodulating myoblast cell line for erythropoietin delivery
Gene Therapy. 2001. DOI : 10.1038/sj.gt.3301356.Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease
Neurobiol Dis. 2001. DOI : 10.1006/nbdi.2001.0388.Insulin-like growth factor-I is necessary for neural stem cell proliferation and demonstrates distinct actions of epidermal growth factor and fibroblast growth factor-2
The Journal of neuroscience. 2001. DOI : 10.1523/JNEUROSCI.21-18-07194.2001.Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome
European Journal of Neuroscience. 2001. DOI : 10.1046/j.0953-816x.2001.01802.x.Encapsulated cell implants as a novel treatment for Parkinson’s disease
Parkinson's disease: Methods and Protocols; Totowa, NJ: Humana Press, 2001. p. 279 - 288.Nerve growth factor- and neurotrophin-3-releasing guidance channels promote regeneration of the transected rat dorsal root
Exp Neurol. 2001. DOI : 10.1006/exnr.2001.7778.Delivery of FGF-2 but not VEGF by encapsulated genetically engineered myoblasts improves survival and vascularization in a model of acute skin flap ischemia
Gene Therapy. 2001. DOI : 10.1038/sj.gt.3301436.Viral vector-mediated gene therapy for Parkinson's disease
Clin Neurosci Res. 2001. DOI : 10.1016/S1566-2772(01)00027-5.Sustained delivery of GDNF: towards a treatment for Parkinson's disease
Brain Res Brain Res Rev. 2001. DOI : 10.1016/S0165-0173(01)00098-4.Recombinant proteins for neurodegenerative diseases: the delivery issue
Trends in Neurosciences. 2001. DOI : 10.1016/S0166-2236(00)01899-3.Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease
Human Gene Therapy. 2000. DOI : 10.1089/10430340050015220.Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease
Human Gene Therapy. 2000. DOI : 10.1089/10430340050016256.Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF
Exp Neurol. 2000. DOI : 10.1006/exnr.2000.7409.Encapsulated neural transplants
Progress in Brain Research. 2000. DOI : 10.1016/S0079-6123(00)27010-6.Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus
The Journal of neuroscience. 2000. DOI : 10.1523/JNEUROSCI.20-15-05587.2000.Efficient gene transfer and expression of biologically active glial cell line-derived neurotrophic factor in rat motoneurons transduced wit lentiviral vectors
Journal of Neurochemistry (JNC). 2000. DOI : 10.1046/j.1471-4159.2000.0741820.x.Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2
Human Molecular Genetics. 2000. DOI : 10.1093/hmg/9.5.803.Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF
Human Gene Therapy. 2000. DOI : 10.1089/10430340050111377.Long-term host unresponsiveness to encapsulated xenogeneic myoblasts after transient immunosuppression
Transplantation. 2000.Gene transfer techniques for the delivery of GDNF in Parkinson's disease
Novartis Foundation symposium. 2000.Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension
Nature biotechnology. 2000. DOI : 10.1038/74473.Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells
Cell Transplant. 2000. DOI : 10.1177/096368970000900404.Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
Science. 2000. DOI : 10.1126/science.290.5492.767.Treatment of diseases of the central nervous system using encapsulated cells
Advances and Technical Standards in Neurosurgery; 1999. p. 3 - 20.Highlights of the cell transplantation meeting at Montreux, March 1999
Cell Transplant. 1999. DOI : 10.1177/096368979900800601.Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis
Annals of Neurology. 1999. DOI : 10.1002/1531-8249(199912)46:6<887::AID-ANA11>3.0.CO;2-L.A surface engineering approach towards the development of cell-based biochip sensors
Lausanne, EPFL, 1998. DOI : 10.5075/epfl-thesis-1848.Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts
Gene Therapy. 1998. DOI : 10.1038/sj.gt.3300687.Attenuation of 6-OHDA-induced neurotoxicity in glutathione peroxidase transgenic mice
European Journal of Neuroscience. 1998. DOI : 10.1046/j.1460-9568.1998.00345.x.Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy
Neuroreport. 1998. DOI : 10.1097/00001756-199806010-00027.Three-dimensional extracellular matrix engineering in the nervous system
J Biomed Mater Res. 1998. DOI : 10.1002/(SICI)1097-4636(19980603)40:3<392::AID-JBM8>3.0.CO;2-C.Application of Teflon-AF thin films for bio-patterning of neural cell adhesion
Biosens Bioelectron. 1998. DOI : 10.1016/S0956-5663(98)00036-0.A gene therapy approach for the treatment of amyotrophic lateral sclerosis and Parkinson's disease
Advances in Pharmacology. 1998. DOI : 10.1016/S1054-3589(08)60899-6.Intrathecal implants of bovine chromaffin cells alleviate mechanical allodynia in a rat model of neuropathic pain
Pain. 1998. DOI : 10.1016/S0304-3959(98)00044-X.In vivo performance of a new biodegradable polyester urethane system used as a nerve guidance channel
Biomaterials. 1998. DOI : 10.1016/S0142-9612(98)00122-7.A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension
Human Gene Therapy. 1997. DOI : 10.1089/hum.1997.8.16-1881.Tissue engineering approaches for peripheral nerve regeneration
Lausanne, EPFL, 1997. DOI : 10.5075/epfl-thesis-1688.The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis
European Journal of Neuroscience. 1997. DOI : 10.1111/j.1460-9568.1997.tb01511.x.GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine
The Journal of neuroscience. 1997. DOI : 10.1523/JNEUROSCI.17-01-00325.1997.Neuronal GDNF expression in the adult rat nervous system identified by in situ hybridization
European Journal of Neuroscience. 1997. DOI : 10.1111/j.1460-9568.1997.tb01623.x.Treatment of Parkinson's disease. Symptomatic cell therapies: cells as biological minipumps
European Neurology. 1996.Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF
Human Gene Therapy. 1996. DOI : 10.1089/hum.1996.7.7-851.Immunoisolated xenogenic chromaffin cell therapy for chronic pain. Initial clinical experience
Anesthesiology. 1996. DOI : 10.1097/00000542-199611000-00007.Combined effects of GDNF, BDNF, and CNTF on motoneuron differentiation in vitro
Journal of Neuroscience Res. 1996. DOI : 10.1002/(SICI)1097-4547(19960415)44:2<133::AID-JNR5>3.0.CO;2-E.Central nervous system delivery of recombinant ciliary neurotrophic factor by polymer encapsulated differentiated C2C12 myoblasts
Human Gene Therapy. 1996. DOI : 10.1089/hum.1996.7.17-2135.The problems of delivering neuroactive molecules to the CNS
Ciba Found Symp. 1996. DOI : 10.1002/9780470514863.ch14.Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients
Nature Medicine. 1996. DOI : 10.1038/nm0696-696.Rescue of motoneurons from axotomy-induced cell death by polymer encapsulated cells genetically engineered to release CNTF
Cell Transplant. 1996. DOI : 10.1016/0963-6897(96)00081-4.Treatment of amyotrophic lateral sclerosis using a gene therapy approach
European Neurology. 1995.Neuronal cell attachment to fluorinated ethylene propylene films with covalently immobilized laminin oligopeptides YIGSR and IKVAV. II
J Biomed Mater Res. 1995. DOI : 10.1002/jbm.820290614.Hydrogel-based three-dimensional matrix for neural cells
J Biomed Mater Res. 1995. DOI : 10.1002/jbm.820290514.Laminin oligopeptide derivatized agarose gels allow three-dimensional neurite extension in vitro
Journal of Neuroscience Res. 1995. DOI : 10.1002/jnr.490410409.Glial cell line-derived neurotrophic factor (GDNF), a new neurotrophic factor for motoneurones
Neuroreport. 1994. DOI : 10.1097/00001756-199412300-00030.Transplantation in humans of encapsulated xenogeneic cells without immunosuppression. A preliminary report
Transplantation. 1994.Spatial control of neuronal cell attachment and differentiation on covalently patterned laminin oligopeptide substrates
International Journal of Developmental Neuroscience. 1994. DOI : 10.1016/0736-5748(94)90052-3.Enseignement et PhD
A dirigé les thèses EPFL de
Markus Borkenhagen, Solomzi Makohliso, Eric Garrison Fine, Diana Zala, Ali Etemad-Sajadi, Sandrine Guillot, Christophe Lo Bianco, Katarzyna Piorkowska-Stanco, Samareh Azeredo da Silveira Lajaunias, Osiris Marroquin Belaunzaran, Christopher Towne, Julien Dusonchet, Meret Gaugler, Philippe Guillaume Coune, Emilda Pino, Elisabeth Anne Dirren, Aurélien Lathuilière, Wojciech Janusz Bobela, Lu Zheng, Cylia Cloé Rochat